Age-related Macular Degeneration (AMD) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Opthea, Kodiak Sciences, Regenxbio, Alexion, AstraZeneca, Allegro, Apellis, Iveric Bio

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, several major pharma and biotech companies are actively working on various pipeline therapies in the Age-related Macular Degeneration therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Age-related Macular Degeneration (AMD) Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Age-related Macular Degeneration Therapeutics Market.

The report provides a detailed description of the Age-related Macular Degeneration drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Age-related Macular Degeneration Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Age-related Macular Degeneration (AMD) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Age-related Macular Degeneration therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Age-related Macular Degeneration treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Age-related Macular Degeneration drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Age-related Macular Degeneration treatment market.

Learn More about the Clinical and Commercial Development Activities in the Age-related Macular Degeneration Therapeutics Domain @
https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Age-related Macular Degeneration (AMD) Therapeutics Analysis
Age-related Macular Degeneration (AMD) Therapeutics Analysis reveals a multifaceted landscape marked by innovative research and a spectrum of treatment modalities aimed at addressing this prevalent cause of vision loss. Therapies for AMD primarily bifurcate into two categories: anti-vascular endothelial growth factor (anti-VEGF) drugs and emerging treatments targeting alternative pathways involved in AMD progression. Anti-VEGF agents like ranibizumab, aflibercept, and bevacizumab have been pivotal in managing neovascular or "wet" AMD by inhibiting abnormal blood vessel growth in the retina.

However, challenges persist, including the need for frequent injections and resistance to treatment in some patients. Researchers are exploring diverse approaches, such as sustained-release drug delivery systems, gene therapies, complement inhibitors, and regenerative medicine, aiming to develop longer-lasting treatments and address different subtypes of AMD. The landscape is also witnessing a shift towards personalized medicine, leveraging genetic insights to tailor therapies based on individual patient characteristics. Clinical trials are investigating novel targets and combination therapies, offering promise for more effective, targeted, and durable treatments that may revolutionize the management of AMD and potentially prevent vision loss in affected individuals.

Age-related Macular Degeneration Companies in the Therapeutics Market Include:
Alkahest Inc, Alexion Pharmaceuticals, Allegro Ophthalmics, Alkeus Pharmaceuticals, Apellis Pharmaceuticals, AstraZeneca, Annexon Biosciences, Clearside Biomedical, CellCure Neurosciences, Evergreen Therapeutics, Gyroscope Therapeutics, Gemini Therapeutics, Graybug Vision, Ionis Pharmaceuticals, Iveric Bio, Kodiak Sciences Inc., Luxa Biotechnology, NGM Biopharmaceuticals, Novartis, Opthea Limited, Outlook Therapeutics, Inc., PanOptica, REGENXBIO, Regeneron Pharmaceuticals, Regenerative Patch Technologies, Ribomic USA Inc., Roche, Stealth BioTherapeutics, Unity Biotechnology Inc., and numerous other companies collectively contributing to the development of new therapies for the treatment of Age-related Macular Degeneration.

Emerging and Marketed Age-related Macular Degeneration (AMD) Therapies Covered in the Report Include:
• OPT-302: Opthea Limited
• KSI-301: Kodiak Sciences Inc.
• RGX-314: Regenxbio
• Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca
• EG-301: Evergreen Therapeutics
• Pegcetacoplan: Apellis Pharmaceuticals
• Zimura: Iveric bio
• Luminate: Allegro Ophthalmics
• NGM621: NGM Biopharmaceuticals
• Elamipretide: Stealth BioTherapeutics
• CPCB-RPE1: Regenerative Patch Technologies
• OpRegen: CellCure Neurosciences/Lineage Cell Therapeutics/Roche
• GT005: Gyroscope Therapeutic
And Many Others

Get an in-depth Assessment of the Emerging Therapies and Age-related Macular Degeneration Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Age-related Macular Degeneration Current Treatment Patterns
4. Age-related Macular Degeneration - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Age-related Macular Degeneration Late-Stage Products (Phase-III)
7. Age-related Macular Degeneration Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Age-related Macular Degeneration Discontinued Products
13. Age-related Macular Degeneration Product Profiles
14. Age-related Macular Degeneration Companies
15. Age-related Macular Degeneration Drugs
16. Dormant and Discontinued Products
17. Age-related Macular Degeneration Unmet Needs
18. Age-related Macular Degeneration Future Perspectives
19. Age-related Macular Degeneration Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.